Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN1 | P18031 | 1/20 | 0.67 |
| ▸ | BCHE | P06276 | 2/20 | 0.46 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.46 |
| ▸ | LTA4H | P09960 | 1/20 | 0.45 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.45 |
| ▸ | MGLL | Q99685 | 2/20 | 0.45 |
| ▸ | NPC1 | O15118 | 2/20 | 0.43 |
| ▸ | RAB9A | P51151 | 2/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.43 |
| ▸ | PKM | P14618 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | PTGER1 | P34995 | 1/20 | 0.43 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6287247 | 1.00 | PTPN1 (0.67) | PTPN1BCHEHRH3LTA4HEPHX2 | |
| SCHEMBL6282831 | 1.00 | PTPN1 (0.67) | PTPN1BCHEHRH3LTA4HEPHX2 | |
| SCHEMBL6287192 | 1.00 | PTPN1 (0.67) | PTPN1BCHEHRH3LTA4HEPHX2 | |
| SCHEMBL6287327 | 0.99 | PTPN1 (0.65) | PTPN1BCHEHRH3LTA4HEPHX2 | |
| SCHEMBL6285933 | 0.91 | PTPN1 (0.56) | PTPN1BCHELTA4HEPHX2MGLL | |
| SCHEMBL6279663 | 0.91 | PTPN1 (0.56) | PTPN1LTA4HNPC1RAB9AL3MBTL1 | |
| SCHEMBL6279323 | 0.91 | PTPN1 (0.56) | PTPN1LTA4HNPC1RAB9AL3MBTL1 | |
| SCHEMBL6285972 | 0.91 | PTPN1 (0.56) | PTPN1LTA4HNPC1RAB9AL3MBTL1 | |
| SCHEMBL6285976 | 0.91 | PTPN1 (0.56) | PTPN1BCHELTA4HEPHX2MGLL | |
| SCHEMBL6282177 | 0.91 | PTPN1 (0.56) | PTPN1LTA4HNPC1RAB9AL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6911468-B2 | Tyrosine phosphatase inhibitors | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 2005-06-28 | — | — | US | disclosed |
| US-20030144338-A1 | Tyrosine phosphatase inhibitors | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2003-07-31 | — | — | US | disclosed |
| EP-1284260-A1 | TYROSINE PHOSPHATASE INHIBITORS | Takeda Chemical Industries, Ltd. (JP) | 2003-02-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030144338-A1 | Tyrosine phosphatase inhibitors | PTPRC, PTPN1, PTPRM | PTPN1 2/4885BCHE 4082/4885HRH3 1166/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.